Novartis wins Jakavi green light in Europe; Zydus Cadila launches Indian Sovaldi copies;

@FiercePharma: ICYMI yesterday: All clear for Actavis to become Allergan as EU watchdogs approve $66B merger. Article | Follow @FiercePharma

@EricPFierce: DEA says it is not the cause of shortages of scheduled drugs, that it is just misunderstood. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

> A New York federal judge has granted early approval to a $400 million settlement ending a class action lawsuit accusing Pfizer ($PFE) of misleading investors about off-label marketing. Report (sub. req.)

> Novartis ($NVS) has won EU approval for Jakavi in polycythemia vera. Release

> Merck KGaA has placed a $4 billion bond with institutional investors to help fund its $17 billion acquisition of Sigma-Aldrich ($SIAL). Report

> Sanofi's ($SNY) Indian affiliate, Shantha Biotechnics, will provide up to 37 million doses of pediatric vaccine Shan5. Release

> India's Zydus Cadila has launched a generic version of Gilead's ($GILD) hepatitis C star Sovaldi in its home country under the brand name SoviHep. Report

Medical Device News

@FierceMedDev: Illumina hits U.K. company with prenatal test patent suit. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: J&J hosts oral biologics startup at its new incubator to help it find Remicade's replacement. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: FDA warning on power morcellators triggers "broad transformation" in clinical practice. WSJ story (sub. req.) | Follow @EmilyWFierce

> Fast-spreading CRISPR tech inspires new preclinical work on blood cancers. Story

> Physicians opt out of morcellator procedures months after FDA warning. Report

> Medtronic backs diabetes device connectivity, analysis startup Glooko in $16.5M Series B. Article

Biotech News

@FierceBiotech: ICYMI yesterday: Department reorganizations at Biogen Idec raise fears of future cuts. Report | Follow @FierceBiotech

@JohnCFierce: $KITE sees its TCR work as a key distinguishing factor in an increasingly crowded field. Sets up Kite EU in $21M deal. Release | Follow @JohnCFierce

> Esperion's potential PCSK9 spoiler scores more positive data. News

> Galapagos registers another setback as J&J dumps anti-inflammatory pact. Story

> CAR-T player Kite Pharma buys its way into Europe and pads its anticancer arsenal. Article

> GlaxoSmithKline and J&J back a $100M new Alzheimer's R&D project. Report

Drug Delivery News

> Efforts at intracochlear drug delivery to treat hearing loss gaining momentum. Item

> Depomed picks up loan for second half of $1.05B Nucynta acquisition from J&J. More

> New optogenetics technique does away with genetic modification. Story

> Glide touts studies of its delivery system as it prepares to take on Novartis' Sandostatin. Item

> J&J hosts oral biologics startup at its new incubator to help it find Remicade's replacement. Article

Pharma Manufacturing News

> Malaysia's CCM Duopharma Biotech adds plants to compete better. More

> Actavis becomes Allergan and looks to manufacturing for cutting costs. Item

> WuXi to bulk up cell therapy manufacturing in Philadelphia. Article

> New York set to get another drug manufacturing project. Story

> Florida CDMO gets taxpayer boost for expansion, 100 jobs. Report

Pharma Asia News

> Astellas says stem cell research promising on kidney failure. Item

> India and U.S. scientists battle over virulence of swine flu strain in India. Report

> Big Three Asia pharma markets poised to soar in 2015, reports say. Story

> South Korea's Green Cross pushes into cell therapy manufacturing in China. More

> Doctor outreach at heart of Daiichi Sankyo $39 million Medicaid lawsuit settlement. Article

And Finally... "Gone Girl" actress Carrie Coon will star in the world premier of "Placebo," a play about a pharma researcher administering a trial for a new female arousal drug. More (sub. req.)

Suggested Articles

Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion.

BMS executives pointed to upcoming Opdivo data releases, as well as strong demand for other drugs in the portfolio, as reasons for optimism.

President Trump is set to issue an executive order centering on U.S. production for drugs and medical supplies, and pharma is sure to push back.